^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    exlinkibart (LVGN6051)

    i
    Other names: LVGN6051, LVGN 6051, LVGN-6051
    Associations

    News

    Trials
    Company:
    Lyvgen
    Drug class:
    CD137 agonist
    Related drugs:
    Associations

    News

    Trials
    21d
    A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue Sarcoma (clinicaltrials.gov)
    P1/2, N=39, Completed, Lyvgen Biopharma Holdings Limited | Recruiting --> Completed | N=65 --> 39 | Trial primary completion date: Mar 2025 --> Dec 2025
    Trial completion • Enrollment change • Trial primary completion date • IO biomarker
    |
    Focus V (anlotinib) • exlinkibart (LVGN6051)
    22d
    Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=66, Completed, Lyvgen Biopharma Holdings Limited | Active, not recruiting --> Completed | N=126 --> 66
    Trial completion • Enrollment change • First-in-human
    |
    dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    22d
    A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=64, Active, not recruiting, Lyvgen Biopharma Holdings Limited | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • exlinkibart (LVGN6051)
    22d
    KEYNOTE-A31: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=105, Completed, Lyvgen Biopharma Holdings Limited | Active, not recruiting --> Completed | N=276 --> 105
    Trial completion • Enrollment change • First-in-human
    |
    Keytruda (pembrolizumab) • exlinkibart (LVGN6051)
    over1year
    Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=352, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Combination therapy • Metastases
    |
    CD40 (CD40 Molecule)
    |
    Avastin (bevacizumab) • albumin-bound paclitaxel • cyclophosphamide • dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    over1year
    KEYNOTE-A31: Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=276, Active, not recruiting, Lyvgen Biopharma Holdings Limited | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Oct 2024 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • exlinkibart (LVGN6051)
    over1year
    Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=126, Active, not recruiting, Lyvgen Biopharma Holdings Limited | Recruiting --> Active, not recruiting | Phase classification: P1a/1b --> P1 | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    dalnicastobart (LVGN7409) • exlinkibart (LVGN6051) • pradusinstobart (LVGN3616)
    almost2years
    A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=64, Recruiting, Lyvgen Biopharma Holdings Limited | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • exlinkibart (LVGN6051)
    2years
    A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) (clinicaltrials.gov)
    P2, N=64, Not yet recruiting, Lyvgen Biopharma Holdings Limited
    New P2 trial • Combination therapy • Metastases
    |
    paclitaxel • Loqtorzi (toripalimab-tpzi) • exlinkibart (LVGN6051)
    2years
    Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=18, Completed, Lyvgen Biopharma Holdings Limited | Terminated --> Completed
    Trial completion • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • exlinkibart (LVGN6051)
    2years
    Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=18, Terminated, Lyvgen Biopharma Holdings Limited | N=50 --> 18 | Trial completion date: Jul 2024 --> Oct 2023 | Recruiting --> Terminated | Trial primary completion date: Apr 2024 --> Oct 2023; The study was terminated due to product development strategy adjustment,there were no safety concerns.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • exlinkibart (LVGN6051)
    over2years
    Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (MK-3475-A31/KEYNOTE-A31) in Advanced or Metastatic Malignancy (clinicaltrials.gov)
    P1, N=276, Recruiting, Lyvgen Biopharma Holdings Limited | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Oct 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • exlinkibart (LVGN6051)